AF burden is important - Fact or fiction?

International Journal of Clinical Practice

Volumn 68, Issue 4, 2014, Pages 444-452

  Boriani, G ^a   Diemberger, I ^a   Ziacchi, M ^a   Valzania, C ^a   Gardini, B ^a   Cimaglia, P ^a   Martignani, C ^a   Biffi, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

ABLATION THERAPY; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DECISION MAKING; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; EMBOLISM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; THROMBOEMBOLISM; AMBULATORY ELECTROCARDIOGRAPHY; ATRIAL FIBRILLATION; COMPLICATION; COST OF ILLNESS; STROKE; TIME FACTOR;

ATRIAL FIBRILLATION; COST OF ILLNESS; ELECTROCARDIOGRAPHY, AMBULATORY; HUMANS; RISK FACTORS; STROKE; THROMBOEMBOLISM; TIME FACTORS;

EID: 84897069577     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12326     Document Type: Review

References (61)

1. Boriani G, Diemberger I, Martignani C, Biffi M, Branzi A,. The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems. Eur Heart J 2006; 27 (8): 893-4.
2. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012; 14 (1): 8-27.
3. Boriani G, Cervi E, Diemberger I, Martignani C, Biffi M,. Clinical management of atrial fibrillation: need for a comprehensive patient-centered approach. Chest 2011; 140 (4): 843-5.
4. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369-429.
5. Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33 (21): 2719-47.
6. Lip GY,. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 2013; 34 (14): 1041-9.
7. Boriani G, Biffi M, Diemberger I, Martignani C, Branzi A,. Rate control in atrial fibrillation: choice of treatment and assessment of efficacy. Drugs 2003; 63 (14): 1489-509.
8. Israel CW, Grönefeld G, Ehrlich JR, Li YG, Hohnloser SH,. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43 (1): 47-52.
9. Savelieva I, Camm AJ,. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000; 4 (2): 369-82.
10. Flaker GC, Belew K, Beckman K, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149 (4): 657-63.
11. Camm AJ, Corbucci G, Padeletti L,. Usefulness of continuous electrocardiographic monitoring for atrial fibrillation. Am J Cardiol 2012; 110 (2): 270-6.
12. McManus DD, Lee J, Maitas O, et al. A novel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation. Heart Rhythm 2013; 10 (3): 315-9.
13. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009; 20 (3): 241-8.
14. Khoo CW, Krishnamoorthy S, Lim HS, Lip GY,. Atrial fibrillation, arrhythmia burden and thrombogenesis. Int J Cardiol 2012; 157 (3): 318-23.
15. Pollak WM, Simmons JD, Interian A Jr, et al. Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter. Pacing Clin Electrophysiol 2001; 24 (4 Pt 1): 424-9.
16. Purerfellner H, Gillis AM, Holbrook R, Hettrick DA,. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol 2004; 27 (7): 983-92.
17. Saksena S, Hettrick DA, Koehler JL, Grammatico A, Padeletti L,. Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias. Am Heart J 2007; 154 (5): 884-92.
18. Ricci R, Santini M, Padeletti L, et al. Atrial tachyarrhythmia recurrence temporal patterns in bradycardia patients implanted with antitachycardia pacemakers. J Cardiovasc Electrophysiol 2004; 15 (1): 44-51.
19. Padeletti L, Santini M, Boriani G, et al. Temporal variability of atrial tachyarrhythmia burden in bradycardia-tachycardia syndrome patients. Eur Heart J 2005; 26 (2): 165-72.
20. Botto GL, Santini M, Padeletti L, et al. Temporal variability of atrial fibrillation in pacemaker recipients for bradycardia: implications for crossover designed trials, study sample size, and identification of responder patients by means of arrhythmia burden. J Cardiovasc Electrophysiol 2007; 18 (3): 250-7.
21. Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005; 112 (3): 307-13.
22. Martinek M, Nesser HJ, Aichinger J, Boehm G, Purerfellner H,. Accuracy of integration of multislice computed tomography imaging into three-dimensional electroanatomic mapping for real-time guided radiofrequency ablation of left atrial fibrillation-influence of heart rhythm and radiofrequency lesions. J Interv Card Electrophysiol 2006; 17 (2): 85-92.
23. Pokushalov E, Romanov A, Corbucci G, et al. Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? Heart Rhythm 2012; 9 (9): 1375-9.
24. Arya A, Silberbauer J, Teichman SL, Milner P, Sulke N, Camm AJ,. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace 2009; 11 (4): 458-64.
25. Ezekowitz MD, Nagarakanti R, Lubinski A, et al. A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol 2012; 34 (1): 1-9.
26. Glotzer TV, Hellkamp AS, Zimmerman J, et al.; MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003; 107 (12): 1614-9.
27. Capucci A, Santini M, Padeletti L, et al.; Italian AT500 Registry Investigators. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005; 46 (10): 1913-20.
28. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009; 2 (5): 474-80.
29. Ziegler PD, Glotzer TV, Daoud EG, et al. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. Stroke 2010; 41 (2): 256-60.
30. 2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke 2011; 42 (6): 1768-70.
31. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366 (2): 120-9.
32. Shanmugam N, Boerdlein A, Proff J, et al. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace 2012; 14 (2): 230-7.
33. Boriani G, Glotzer TV, Santini M, et al. Device detected atrial filbrillation and risk for stroke: an analysis of more than 10,000 patients from the SOS AF project (Stroke Prevention Strategies based on Atrial Filbrillation inform from implanted devices). Eur Heart J 2013;. doi: 10.1093/eurheartj/ eht491.
34. Lamas G,. How much atrial fibrillation is too much atrial fibrillation? N Engl J Med 2012; 366 (2): 178-80.
35. Boriani G, Santini M, Lunati M, et al. Improving thromboprophylaxis using atrial fibrillation diagnostic capabilities in implantable cardioverter- defibrillators: the multicentre Italian ANGELS of AF Project. Circ Cardiovasc Qual Outcomes 2012; 5: 182-8.
36. Lim HS, Lip GY,. Asymptomatic atrial fibrillation on device interrogation. J Cardiovasc Electrophysiol 2008; 19 (8): 891-3.
37. Ip J, Waldo AL, Lip GY, et al.; IMPACT Investigators. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. Am Heart J 2009; 158 (3): 364-70.
38. Daoud EG, Glotzer TV, Wyse DG, et al.; TRENDS Investigators. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011; 8 (9): 1416-23.
39. The French Study of Aortic Plaques in Stroke Group. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996; 334: 1216-21.
40. Benjamin EJ, Plehn JF, D'Agostino RB, et al. Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med 1992; 327 (6): 374-9.
41. Stein JH, Soble JS,. Thrombus associated with mitral valve calcification: a possible mechanism for embolic stroke. Stroke 1995; 26: 1697-9.
42. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ,. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37 (2): 371-8.
43. Boriani G, Auricchio A, Klersy C, et al.; European Heart Rhythm Association; Eucomed. Healthcare personnel resource burden related to in-clinic follow-up of cardiovascular implantable electronic devices: a European Heart Rhythm Association and Eucomed joint survey. Europace 2011; 13 (8): 1166-73.
44. Boriani G, Diemberger I, Martignani C, et al. Telecardiology and remote monitoring of implanted electrical devices: the potential for fresh clinical care perspectives. J Gen Intern Med 2008; 23 (Suppl. 1): 73-7.
45. Varma N, Ricci RP,. Telemedicine and cardiac implants: what is the benefit? Eur Heart J 2013; 34 (25): 1885-95.
46. Burri H, Heidbüchel H, Jung W, Brugada P,. Remote monitoring: a cost or an investment? Europace 2011; 13 (Suppl. 2): ii44-8.
47. Boriani G, Maniadakis N, Auricchio A, et al. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. Eur Heart J 2013; 34 (25): 1869-74.
48. Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH,; CONNECT Investigators. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol 2011; 57 (10): 1181-9.
49. Landolina M, Perego GB, Lunati M, et al. Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study. Circulation 2012; 125 (24): 2985-92.
50. Boriani G, Da Costa A, Ricci RP, et al. The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) randomized controlled trial: phase 1 results on early decision making with remote monitoring. J Med Internet Res 2013; 15 (8): e167.
51. Boriani G, Burri H, Mantovani LG, et al. Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. Europace 2011; 13 (Suppl. 2): ii59-65.
52. Ricci RP, Morichelli L, Gargaro A, Laudadio MT, Santini M,. Home monitoring in patients with implantable cardiac devices: is there a potential reduction of stroke risk? Results from a computer model tested through Monte Carlo simulations. J Cardiovasc Electrophysiol 2009; 20 (11): 1244-51.
53. Boriani G, Diemberger I, Mantovani V, Biffi M, Martignani C,. Remote monitoring of patients with an implanted device and patients' outcomes: the potential for "win-win" dynamics. J Cardiovasc Electrophysiol 2009; 20 (11): 1252-4.
54. Boriani G, Diemberger I, Biffi M, Martignani C,. Cost-effectiveness of cardiac resynchronisation therapy. Heart 2012; 98 (24): 1828-36.
55. Seet RC, Friedman PA, Rabinstein AA,. Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 2011; 124 (4): 477-86.
56. Huber K, Connolly SJ, Kher A, et al. Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Int J Clin Pract 2013; 67 (6): 516-26.
57. Harris K, Mant J,. Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. Int J Clin Pract 2013; 67 (7): 647-55.
58. Sinha AM, Diener HC, Morillo CA, et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. Am Heart J 2010; 160 (1): 36-41.e1.
59. Cotter PE, Martin PJ, Ring L, Warburton EA, Belham M, Pugh PJ,. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology 2013; 80 (17): 1546-50.
60. Ritter MA, Kochhäuser S, Duning T, et al. Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors. Stroke 2013; 44 (5): 1449-52.
61. Etgen T, Hochreiter M, Mundel M, Freudenberger T,. Insertable cardiac event recorder in detection of atrial fibrillation after cryptogenic stroke: an audit report Stroke 2013; 44 (7): 2007-9.